Table 2.

Comparison of pCR rates, with 95% confidence intervals (lower panel), among the regimens according to hormone receptor status

Regimen	Overall	P	HR+	P	HR−	P
3-wP/FAC versus wP/FAC	28% versus 44%	0.05	19% versus 25%	0.39	40% versus 65%	0.07
3-wP/FAC versus H + 3-wP/FEC	28% versus 54%	0.003	19% versus 47%	0.01	40% versus 61%	0.09
wP/FAC versus H + 3-wP/FEC	44% versus 54%	0.24	25% versus 47%	0.04	65% versus 61%	0.46

	Overall			HR+			HR−
	Mean	95% CI		Mean	95% CI		Mean	95% CI
Treatment groups
H + 3-wP/FEC	0.539	0.436	0.643	0.465	0.316	0.614	0.609	0.468	0.750
wP/FAC	0.444	0.322	0.567	0.250	0.100	0.400	0.645	0.477	0.814
3-wP/FAC	0.277	0.149	0.404	0.185	0.039	0.332	0.400	0.185	0.615
Grand total	0.447	0.378	0.516	0.324	0.233	0.414	0.577	0.479	0.676

pCR, pathologic complete response; HR, hormone receptor (estrogen or progesterone receptor); 3-w, 3-weekly; P, paclitaxel; FAC, fluorouracil, doxorubicin, and cyclophosphamide; FEC, fluorouracil, epirubicin, and cyclophosphamide; H, trastuzumab; CI, confidence interval.